| Literature DB >> 28978050 |
Hongmei Han1, Jianxia Zhang1, Jianghong Hou1, Haibo Wang1, Jianpeng Zheng1, Huan Wang1, Zhong Zhong1, Yijin Wang1, Xiaoni Wang1, Bei Yang1, Lei Wang1, Dangjun Quan1, Junnong Li1.
Abstract
Genome-wide association studies have identified that TERT gene was associated with telomere length and age-related diseases. However, little study directly focused on the association between TERT gene polymorphisms and risk of coronary heart disease (CHD). We conducted a case-control study to examine the effect of TERT polymorphisms on CHD risk among 596 CHD patients and 603 healthy controls from China. Five significant single nucleotide polymorphisms (SNP) in TERT were selected and genotyped using Sequenom Mass-ARRAY technology. Odds ratios (OR) and 95% confidence intervals (CIs) were calculated using unconditional logistic regression adjusting for age and gender. Allelic model analysis revealed that for TERT rs10069690, allele frequency distributions differed between cases and controls (OR= 1.267, 95%CI = 1.018-1.576; p = 0.034). Genotypic model analysis revealed that genotype frequency distributions of rs10069690 differed between cases and controls after adjusted by age and sex (TC vs. CC: adjusted OR = 1.352, 95% CI = 1.007-1.815; p = 0.045). Genetic model analysis revealed that rs10069690 was associated with an increased risk of CHD under co-dominant, dominant, over-dominant and log-additive models. After adjustments, it remained significant under over-dominant model (adjusted OR = 1.35, 95% CI = 1.01-1.81; p = 0.044). Our results shed new light on the association between telomere-related gene TERT polymorphisms and CHD susceptibility in a Chinese Han population.Entities:
Keywords: TERT; case-control study; coronary heart disease (CHD); single nucleotide polymorphisms (SNP); telomere
Year: 2017 PMID: 28978050 PMCID: PMC5620190 DOI: 10.18632/oncotarget.18727
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Characteristics of cases and controls included in this study
| Variables | Case (N=596) | Control (N=603) | |
|---|---|---|---|
| Sex, No.(%) | < 0.001a | ||
| Male | 376 | 469 | |
| Female | 220 | 134 | |
| Mean age ±SD | 61.44 ±11.16 | 48.24 ±13.05 | < 0.001b |
aThe p value was calculated from Pearson’s chi-square tests.
bThe p value was calculated by Welch’s t tests.
SD, standard deviation.
Allele frequencies in cases and controls and odds ratio estimates for CHD
| SNP ID | Band | Position | Gene | Alleles Aa/B | MAF | HWE | ORs(95%CI) | ||
|---|---|---|---|---|---|---|---|---|---|
| Case | Control | ||||||||
| rs2075786 | 5p15.33 | 1266310 | G/A | 0.163 | 0.162 | 0.879 | 1.003(0.806-1.248) | 0.981 | |
| rs10069690 | 5p15.33 | 1279790 | T/C | 0.180 | 0.147 | 0.190 | 1.267(1.018-1.576) | 0.034* | |
| rs2242652 | 5p15.33 | 1280028 | A/G | 0.171 | 0.163 | 0.549 | 1.064(0.858-1.319) | 0.571 | |
| rs2853677 | 5p15.33 | 1287194 | G/A | 0.377 | 0.366 | 0.793 | 1.048(0.888-1.237) | 0.577 | |
| rs2853676 | 5p15.33 | 1288547 | T/C | 0.175 | 0.154 | 0.756 | 1.164(0.937-1.444) | 0.169 | |
SNP, single nucleotide polymorphism; MAF, minor allelic frequency; HWE, Hardy-Weinberg equilibrium; ORs, odds ratios; CI, confidence interval
aMinor allele; *p value ≤ 0.05 indicates statistical significance;
Genotypes frequencies of the SNPs and their associations with risk of CHD
| SNP ID | Alleles A/B | Genotype | Genotype frequencies | Without adjustment | With adjustment | |||
|---|---|---|---|---|---|---|---|---|
| Case | Control | OR(95%CI) | OR(95%CI) | |||||
| rs2075786 | G/A | AA | 419(70.3%) | 411(70.3%) | 1.00 | 1.00 | ||
| GA | 160(26.8%) | 158(27.0%) | 0.993(0.767-1.286) | 0.960 | 0.925(0.688-1.243) | 0.605 | ||
| GG | 17(2.9%) | 16(2.7%) | 1.042(0.520-2.091) | 0.907 | 0.972(0.431-2.191) | 0.945 | ||
| rs10069690 | T/C | CC | 396(66.4%) | 436(73.4%) | 1.00 | 1.00 | ||
| TC | 186(31.2%) | 141(23.7%) | 1.452(1.122-1.879) | 0.004* | 1.352(1.007-1.815) | 0.045* | ||
| TT | 14(2.4%) | 17(2.9%) | 0.907(0.441-1.863) | 0.790 | 1.020(0.452-2.301) | 0.961 | ||
| rs2242652 | A/G | GG | 404(67.8%) | 425(70.5%) | 1.00 | 1.00 | ||
| AG | 180(30.2%) | 160(26.5%) | 1.183(0.919-1.524) | 0.192 | 1.088(0.817-1.453) | 0.569 | ||
| AA | 12(2.0%) | 18(3.0%) | 0.701(0.334-1.474) | 0.349 | 0.693(0.297-1.616) | 0.396 | ||
| rs2853677 | G/A | AA | 225 (37.8%) | 244 (40.5%) | 1.00 | 1.00 | ||
| GA | 293 (49.2%) | 277 (46.0%) | 1.147(0.898-1.465) | 0.271 | 1.163(0.880-1.535) | 0.288 | ||
| GG | 78 (13.0%) | 82 (13.5%) | 1.032(0.720-1.477) | 0.865 | 1.259(0.834-1.902) | 0.272 | ||
| rs2853676 | T/C | CC | 405(68.0%) | 429(71.3%) | 1.00 | 1.00 | ||
| TT | 173(29.0%) | 160(26.6%) | 1.145(0.888-1.477) | 0.296 | 1.153(0.862-1.544) | 0.337 | ||
| TC | 18(3.0%) | 13(2.1%) | 1.467(0.710-3.032) | 0.301 | 1.896(0.838-4.290) | 0.124 | ||
SNP, single nucleotide polymorphism; OR, odds ratio; 95%CI, 95% confidence interval.
aP values were calculated from unconditional logistic regression analysis.
bP values were calculated by unconditional logistic regression analysis with adjustments for age and gender.
*P≤0.05 indicates statistical significance.
Association between rs10069690 and risk of CHD in multiple inheritance models (adjusted by age and gender)
| Model | Genotype | Group=case | Group=control | Without adjustment | With adjustment | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | AIC | BIC | OR (95% CI) | AIC | BIC | ||||||
| Co-dominant | C/C | 396 (66.4%) | 436 (73.4%) | 1 | 0.015* | 1647.3 | 1662.5 | 1 | 0.13 | 1356.2 | 1381.6 |
| C/T | 186 (31.2%) | 141 (23.7%) | 1.45 (1.12-1.88) | 1.35 (1.01-1.82) | |||||||
| T/T | 14 (2.4%) | 17 (2.9%) | 0.91 (0.44-1.86) | 1.02 (0.45-2.30) | |||||||
| Dominant | C/C | 396 (66.4%) | 436 (73.4%) | 1 | 0.0088* | 1646.8 | 1657 | 1 | 0.056 | 1354.7 | 1375 |
| C/T-T/T | 200 (33.6%) | 158 (26.6%) | 1.39 (1.09-1.79) | 1.32 (0.99-1.75) | |||||||
| Recessive | C/C-C/T | 582 (97.7%) | 577 (97.1%) | 1 | 0.58 | 1653.4 | 1663.5 | 1 | 0.88 | 1358.3 | 1378.6 |
| T/T | 14 (2.4%) | 17 (2.9%) | 0.82 (0.40-1.67) | 0.94 (0.42-2.11) | |||||||
| Over-dominant | C/C-T/T | 410 (68.8%) | 453 (76.3%) | 1 | 0.0039* | 1645.3 | 1655.5 | 1 | 0.044* | 1354.2 | 1374.5 |
| C/T | 186 (31.2%) | 141 (23.7%) | 1.46 (1.13-1.88) | 1.35 (1.01-1.81) | |||||||
| Log-additive | --- | --- | --- | 1.27 (1.02-1.58) | 0.033* | 1649.1 | 1659.3 | 1.23 (0.96-1.58) | 0.1 | 1355.7 | 1376 |
ORs, odds ratios; CI, confidence interval; AIC, Akaike’s Information criterion; BIC, Bayesian Information criterion.
*p value ≤0.05 indicates statistical significance.
Figure 1D’ linkage map for the five SNPs in TERT
TERT haplotype frequencies and the association with the CHD risk
| Haplotype | rs10069690 | rs2242652 | Freq-case | Freq-control | Without adjustment | With adjustment | ||
|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | |||||||
| 1 | C | G | 0.818 | 0.832 | 1 | --- | 1 | --- |
| 2 | T | A | 0.169 | 0.146 | 1.17 (0.94 - 1.46) | 0.16 | 1.11 (0.86 - 1.44) | 0.41 |
| rare | * | * | 0.013 | 0.022 | 0.61 (0.32 - 1.16) | 0.13 | 0.72 (0.35 - 1.46) | 0.36 |
Freq, frequency; ORs, odds ratios; CI, confidence interval.
Primers used for this study
| SNP_ID | First PCR Primer | Second PCR Primer | UEP SEQ |
|---|---|---|---|
| rs2075786 | ACGTTGGATGCAGGTTACACACGTGGTGAG | ACGTTGGATGCGCCACTCTTGACTTTCCAA | ggCAAAGAGCAGCAGGAGCC |
| rs10069690 | ACGTTGGATGCCTGTGGCTGCGGTGGCTG | ACGTTGGATGATGTGTGTTGCACACGGGAT | GGGATCCTCATGCCA |
| rs2242652 | ACGTTGGATGACAGCAGGACACGGATCCAG | ACGTTGGATGAGGCTCTGAGGACCACAAGA | gtcgGAGGACCACAAGAAGCAGC |
| rs2853677 | ACGTTGGATGATCCAGTCTGACAGTCGTTG | ACGTTGGATGGCAAGTGGAGAATCAGAGTG | gggtAATCAGAGTGCACCAG |
| rs2853676 | ACGTTGGATGTGTCTCCTGCTCTGAGACC | ACGTTGGATGCAAAACTAAGACCCAAGAGG | agatGGAAGTCTGACGAAGGC |
UEP SEQ, unextended mini-sequencing primer.